Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
Moosavi
Zahra
Z
Nakhli
Abdolhamid
A
Rassaii
Sima
S
D000293:Adolescent; D000328:Adult; D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D018320:Leishmania major / Q000187:drug effects; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy* / Q000469:parasitology; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000627:therapeutic use*; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009824:Ointments; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D010303:Paromomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D000981:Antiprotozoal Agents; D009824:Ointments; D009942:Organometallic Compounds; D010303:Paromomycin; D008536:Meglumine; D000077485:Meglumine Antimoniate